TCI Wealth Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.88M Buy
15,431
+268
+2% +$57.7K 0.17% 52
2026
Q1
$3.3M Sell
15,163
-112
-0.7% -$24.8K 0.18% 55
2025
Q4
$3.49M Sell
15,275
-93
-0.6% -$21.2K 0.19% 55
2025
Q3
$3.56M Buy
15,368
+138
+0.9% +$28.1K 0.21% 51
2025
Q2
$2.83M Sell
15,230
-46
-0.3% -$8.55K 0.19% 54
2025
Q1
$3.2M Sell
15,276
-1,106
-7% -$215K 0.26% 40
2024
Q4
$2.91M Buy
16,382
+97
+0.6% +$17.8K 0.24% 40
2024
Q3
$3.22M Sell
16,285
-83
-0.5% -$15.5K 0.27% 40
2024
Q2
$2.81M Sell
16,368
-11
-0.1% -$1.82K 0.26% 42
2024
Q1
$2.98M Sell
16,379
-664
-4% -$114K 0.29% 40
2023
Q4
$2.64M Buy
17,043
+165
+1% +$24.1K 0.28% 39
2023
Q3
$2.52M Buy
16,878
+416
+3% +$61.1K 0.32% 36
2023
Q2
$2.22M Buy
16,462
+18
+0.1% +$2.64K 0.28% 40
2023
Q1
$2.62M Sell
16,444
-304
-2% -$46.5K 0.34% 34
2022
Q4
$2.71M Sell
16,748
-27
-0.2% -$4.14K 0.37% 33
2022
Q3
$2.25M Buy
16,775
+142
+0.9% +$20.4K 0.36% 32
2022
Q2
$2.55M Buy
16,633
+218
+1% +$33.3K 0.39% 31
2022
Q1
$2.66M Buy
16,415
+517
+3% +$75.1K 0.4% 26
2021
Q4
$2.15M Sell
15,898
-198
-1% -$23.4K 0.32% 36
2021
Q3
$1.74M Sell
16,096
-1,352
-8% -$154K 0.26% 41
2021
Q2
$1.97M Buy
17,448
+1,109
+7% +$125K 0.33% 34
2021
Q1
$1.77M Buy
16,339
+110
+0.7% +$11.8K 0.75% 28
2020
Q4
$1.74M Sell
16,229
-2,961
-15% -$285K 0.78% 26
2020
Q3
$1.68M Buy
19,190
+668
+4% +$62.9K 0.66% 30
2020
Q2
$1.82M Sell
18,522
-6
-0% -$528 0.78% 28
2020
Q1
$1.41M Sell
18,528
-967
-5% -$82.4K 0.7% 33
2019
Q4
$1.73M Sell
19,495
-1,400
-7% -$116K 0.67% 36
2019
Q3
$1.58M Buy
20,895
+2,200
+12% +$151K 0.7% 37
2019
Q2
$1.36M Sell
18,695
-76
-0.4% -$5.97K 0.61% 41
2019
Q1
$1.51M Sell
18,771
-48
-0.3% -$3.93K 0.67% 39
2018
Q4
$1.74M Sell
18,819
-722
-4% -$63.5K 0.84% 31
2018
Q3
$1.85M Buy
19,541
+78
+0.4% +$7.4K 0.77% 34
2018
Q2
$1.8M Buy
19,463
+24
+0.1% +$2.34K 0.8% 33
2018
Q1
$1.84M Sell
19,439
-264
-1% -$29K 0.85% 27
2017
Q4
$1.91M Buy
19,703
+600
+3% +$56.5K 0.84% 27
2017
Q3
$1.7M Buy
19,103
+813
+4% +$61.9K 0.83% 30
2017
Q2
$1.33M Sell
18,290
-246
-1% -$16.5K 0.68% 38
2017
Q1
$1.21M Sell
18,536
-1,384
-7% -$87K 0.63% 41
2016
Q4
$1.25M Buy
19,920
+14
+0.1% +$855 0.65% 39
2016
Q3
$1.25M Buy
19,906
+13
+0.1% +$842 0.68% 36
2016
Q2
$1.23M Buy
19,893
+571
+3% +$34.8K 0.68% 36
2016
Q1
$1.1M Buy
19,322
+1,577
+9% +$87.9K 0.61% 41
2015
Q4
$1.05M Buy
17,745
+101
+0.6% +$5.82K 0.59% 45
2015
Q3
$960K Sell
17,644
-1,851
-9% -$120K 0.58% 44
2015
Q2
$1.31M Buy
19,495
+269
+1% +$17.6K 0.75% 36
2015
Q1
$1.13M Sell
19,226
-277
-1% -$16.7K 0.71% 37
2014
Q4
$1.28M Buy
19,503
+1,163
+6% +$73.3K 0.79% 35
2014
Q3
$1.06M Hold
18,340
0.67% 38
2014
Q2
$1.03M Hold
18,340
0.62% 40
2014
Q1
$942K Hold
18,340
0.61% 39
2013
Q4
$969K Sell
18,340
-1,900
-9% -$93.4K 0.61% 38
2013
Q3
$905K Sell
20,240
-600
-3% -$26.6K 0.69% 37
2013
Q2
$862K Buy
+20,840
New +$911K 0.65% 37

Other funds holding ABBV

TCI Wealth Advisors's ABBV Position: Q2 2026 in Review

TCI Wealth Advisors increased its AbbVie (ABBV) stake by 1.8% in Q2 2026, buying an estimated $57.7K and bringing the position to 15,431 shares worth $3.88M. The position accounts for 0.17% of the portfolio, ranked #52.

TCI Wealth Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • TCI Wealth Advisors held 15,431 shares of AbbVie worth $3.88M as of Q2 2026.
  • TCI Wealth Advisors bought 268 AbbVie shares in Q2 2026, an estimated $57.7K.
  • AbbVie made up 0.17% of TCI Wealth Advisors's portfolio in Q2 2026, its #52 holding.
  • TCI Wealth Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on TCI Wealth Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.